Key Insights

Highlights

Treatment Research

5 treatments under study, led by Ivmp

Research Leaders

13 sponsors active, led by Feng Jinzhou

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 3 (2)

Trial Status

Unknown2
Not Yet Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07231523Phase 3Not Yet RecruitingPrimary

EFG vs IVIG in TAMG

NCT06587867Phase 3UnknownPrimary

Seronegative Myasthenia Gravis - Efgartigimod IV

NCT06118398Unknown

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

Showing all 3 trials

Research Network

Common Treatments

  • Ivmp1
  • Intravenous Immunglobulin Thymectomy1
  • Efgartigimod1
  • Efgartigimod Thymectomy1
  • Intravenous Methylprednisolone Ivmp And Efgartigimod1

Active Sponsors

  • Feng Jinzhou1
  • First Affiliated Hospital of Wenzhou Medical University1
  • Huashan Hospital1
  • Second Affiliated Hospital of Soochow University1
  • Shanghai Zhongshan Hospital1

Top Investigators

Related Conditions

  • Intravenous Immunoglobulin1
  • Generalized Myasthenia Gravis1
  • Myasthenia Gravis Associated With Thymoma1
  • Neuromyelitis Optica1

Activity Timeline